Direct oral anticoagulants are effective and safe for venous thromboembolism with a lower bleeding risk than vitamin K antagonists, though postthrombotic syndrome affects 25% to 40% of patients.
This review highlights that direct oral anticoagulants offer a safer alternative to vitamin K antagonists for VTE management, though postthrombotic syndrome remains a significant chronic complication.
Venous thromboembolism (VTE) is the third most common cardiovascular disorder, affecting up to 5% of the population. VTE commonly manifests as lower-extremity deep venous thrombosis (DVT) or pulmonary embolism. Half of these events are associated with a transient risk factor and may be preventable with prophylaxis. Direct oral anticoagulants are effective and safe and carry a lower risk for bleeding than vitamin K antagonists. Many patients with VTE will have a chronic disease requiring long-term anticoagulation. Postthrombotic syndrome affects 25% to 40% of patients with DVT and significantly impacts function and quality of life.
Lisa Duffett (Thu,) conducted a review in Deep Venous Thrombosis. Direct oral anticoagulants are effective and safe for venous thromboembolism with a lower bleeding risk than vitamin K antagonists, though postthrombotic syndrome affects 25% to 40% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: